Quick Takeaways:
- Cronus Pharma has announced the US launch of Pimobendan Chewable Tablets, available to veterinarians beginning June 9, 2026. The product is the first FDA-approved bioequivalent of Vetmedin and is designed to support the management of canine congestive heart failure, expanding treatment options for veterinarians and pet owners.
- The chewable tablets are indicated for the management of mild, moderate, or severe congestive heart failure in dogs resulting from myxomatous mitral valve disease (MMVD) or dilated cardiomyopathy (DCM). Approved under ANADA #200-728, the product is backed by FDA-reviewed studies and manufacturing standards and can be used alongside other heart failure therapies, including diuretics, when clinically appropriate.
- Cronus Pharma’s Pimobendan Chewable Tablets are supplied in 1.25 mg, 2.5 mg, 5 mg, and 10 mg strengths as half-scored chewable tablets, with 50 tablets per bottle. The product will be available through national and regional veterinary distributors across the US, supporting broad access to canine cardiac care treatments.
Why It Matters?
Cronus Pharma is bringing price competition to a key canine heart failure drug class by launching the first FDA‑approved bioequivalent chewable to Vetmedin, available nationwide through vet distributors.
For the market, this should lower treatment costs in dogs with MMVD- or DCM‑related congestive heart failure, give clinics more flexibility in sourcing a daily, chronic-use cardiology drug, and modestly pressure Boehringer Ingelheim’s Vetmedin franchise while maintaining continuity of care (same strengths, chewable format, and concurrent-use compatibility with standard CHF therapies).
Source: Businesswire
